Tumor PaintTM technology enters clinical stage of development
SEATTLE & MELBOURNE, Australia--(BUSINESS WIRE)--
Bioscience, Inc. and its subsidiary, Blaze Bioscience Australia Pty
Ltd, today announced the initiation of the first Phase 1 clinical study
of the first Tumor Paint product candidate, BLZ-100. The study, titled
“A Phase I Dose Escalation/Expansion Study of BLZ-100 Administered by
Intravenous Injection in Adult Subjects with Skin Cancer,” will enroll
up to 30 patients with basal cell carcinoma, squamous cell carcinoma, or
amelanotic melanoma. The primary objective is to evaluate the safety and
tolerability of BLZ-100 after a single intravenous injection of BLZ-100
administered prior to surgery. The study will also examine the
pharmacokinetics of BLZ-100 and the fluorescent signal from skin tumors.
“Initiation of the first-in-human clinical trial just a little over two
years after moving the technology out of my lab at the Fred Hutchinson
Cancer Research Center is a tremendous accomplishment and marks a major
milestone in the development of the Tumor Paint platform,” said Jim
Olson, M.D., Ph.D., co-founder of Blaze.
“Skin cancer surgery is just one of many cancer surgery settings that we
think could benefit from real-time fluorescent imaging using BLZ-100,”
said Dennis Miller, Ph.D., Senior Vice President of Development. “Blaze
anticipates initiating a U.S. clinical program in additional tumor types
by the end of 2014.”
The study will be conducted at two sites: Q-Pharm Pty Limited and the
dermatology clinic of Specialist Connect Pty Limited, both located in
Brisbane, Queensland, Australia. Dr. Lynda Spelman of Specialist Connect
is the Principal Investigator. Dr. Lauren Kunde and Dr. Paul Griffin are
About Skin Cancer in Australia
Australia has the highest rate of skin cancer in the world. Two out of
three Australians will be diagnosed with some form of skin cancer before
the age of 70. Basal cell carcinoma and squamous cell carcinoma are the
most common types of non-melanoma skin cancer. In Australia, about
430,000 cases of basal cell and squamous cell carcinomas are diagnosed
and treated each year.
BLZ-100 is the first product candidate developed from the Tumor Paint
technology platform. Tumor Paint technology is designed to provide
real-time, high-resolution intraoperative visualization of cancer cells,
enabling better detection and more complete and precise surgical removal
of cancer, and has potential applications in a broad array of solid
tumor cancers. BLZ-100 is a combination of a targeting peptide, which
binds and internalizes into cancer cells, and a fluorescent dye, which
emits light in the near-infrared range. BLZ-100 is under development for
cancer surgery in multiple solid tumor types.
About Blaze Bioscience
Blaze Bioscience is dedicated to developing products that assist
physicians in their quest to improve the lives of cancer patients. Blaze
was co-founded by Dr. Jim Olson of Fred Hutchinson Cancer Research
Center and Heather Franklin, a former senior business executive at
ZymoGenetics, Inc., to develop and commercialize Tumor Paint technology.
For additional information, please visit www.blazebioscience.com.
Julie Rathbun, 206-769-9219
Heather Franklin, CEO and President
Source: Blaze Bioscience, Inc.